Phase 2 MS Clinical Trials

60 active trials · 34 recruiting

60 active phase 2 multiple sclerosis trials are listed here, 34 currently recruiting, sourced from ClinicalTrials.gov.

Phase 2 trials give a treatment to a larger group to look for early signs that it works and to keep checking safety. Positive phase 2 results are what justify a large phase 3 study.

Active Phase 2 MS trials

RecruitingPhase 1

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Cilostazol · Leucovorin

1 state250 participantsDetails ›

RecruitingPhase 2

Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Methylprednisolone · Prednisone

1 state30 participantsDetails ›

RecruitingPhase 1

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

rapcabtagene autoleucel (YTB323)

28 participantsDetails ›

RecruitingPhase 2

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)

Sponsor: Hoffmann-La Roche

RO7268489 · Ocrelizumab

360 participantsDetails ›

RecruitingPhase 2

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)

Sponsor: Hoffmann-La Roche

Ocrelizumab Test Formulation · Ocrelizumab Reference Formulation

8 states182 participantsDetails ›

RecruitingPhase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Sponsor: Celgene

BMS-986368 · Placebo

11 states200 participantsDetails ›

RecruitingPhase 1

Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis

Sponsor: Tr1X, Inc.

TRX319 · Bendamustine

2 states39 participantsDetails ›

RecruitingPhase 2

The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis

Sponsor: Cairo University

Rituximab · Saline (NaCl 0,9 %) (placebo)

46 participantsDetails ›

RecruitingPhase 1

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

Sponsor: University of California, San Francisco

Clemastine Fumarate · Placebo

1 state74 participantsDetails ›

RecruitingPhase 2

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib

12 participantsDetails ›

RecruitingPhase 1

Molecular Imaging of NET Using [C-11]MRB-PET in MS

Sponsor: Brigham and Women's Hospital

[C-11]Methylreboxetine

1 state19 participantsDetails ›

RecruitingPhase 1

PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases

Sponsor: Brigham and Women's Hospital

[F-18]PBR06 · [C-11]PBR28

1 state250 participantsDetails ›

RecruitingPhase 2

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Sponsor: Queen Mary University of London

Tyruko Injectable Product · Placebo

40 participantsDetails ›

RecruitingPhase 2

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Sponsor: ModernaTX, Inc.

mRNA-1195 · Placebo

5 states180 participantsDetails ›

RecruitingPhase 2

Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)

Sponsor: State University of New York at Buffalo

metformin · Placebo

1 state30 participantsDetails ›

RecruitingPhase 1

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

Sponsor: Novartis Pharmaceuticals

rapcabtagene autoleucel (YTB323)

28 participantsDetails ›

RecruitingPhase 2

A Study of Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Sponsor: Tiziana Life Sciences LTD

Foralumab · Placebo

5 states54 participantsDetails ›

RecruitingPhase 2

Comparing Telehealth-Delivered CBT-I to Web-Based CBT-I to Enhance Sleep, Reduce Fatigue, and Promote Neuroprotection

Sponsor: University of Kansas Medical Center

Telehealth cognitive behavioral thera… · Web-based cognitive behavioral therap…

1 state90 participantsDetails ›

RecruitingPhase 1

A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis

Sponsor: The Hospital for Sick Children

Metformin · Placebo

20 participantsDetails ›

RecruitingPhase 1

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT7208 in Healthy Participants and MS Patients

Sponsor: Vidya Therapeutics Inc

VT7208 · Placebo

100 participantsDetails ›

RecruitingPhase 2

Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)

Sponsor: NYU Langone Health

Active tDCS · Sham tDCS

1 state170 participantsDetails ›

RecruitingPhase 2

MODAFIMS: A Trial to Evaluate Predictors of Response to MODAFinil in Patients With Multiple Sclerosis

Sponsor: Clinical Academic Center (2CA-Braga)

Modafinil Generis 100 mg

64 participantsDetails ›

RecruitingPhase 1

Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis

Sponsor: Ever Supreme Bio Technology Co., Ltd.

Allogeneic umbilical cord mesenchymal… · Control group

41 participantsDetails ›

RecruitingPhase 2

Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype

Sponsor: Tiffany J. Braley, MD, MS

Cannabidiol (CBD) · Tetrahydrocannabinol (THC)

1 state166 participantsDetails ›

RecruitingPhase 2

Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis

Sponsor: University of Kansas Medical Center

Cognitive behavioral therapy for inso… · Sleep and lifestyle education

1 state70 participantsDetails ›

RecruitingPhase 2

TOTEM RRMS : TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis

Sponsor: University Hospital, Strasbourg, France

Nebido® Testosterone Undecanoate 1000… · Placebo 4 mL Solution for Injection

40 participantsDetails ›

RecruitingPhase 2

Solriamfetol for the Treatment of Multiple Sclerosis Fatigue

Sponsor: Johns Hopkins University

Solriamfetol · Placebo

1 state46 participantsDetails ›

RecruitingPhase 2

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Sponsor: Tiziana Life Sciences LTD

Foralumab TZLS-401 100 µg

1 state55 participantsDetails ›

RecruitingPhase 2

Illuminating New Paths in the Treatment of Multiple Sclerosis Relapses - Early and Specialized Rehabilitation

Sponsor: Lars Hvid

Intensive rehab · Usual care

64 participantsDetails ›

RecruitingPhase 1

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

Sponsor: Ashvattha Therapeutics, Inc.

18F-OP-801

2 states65 participantsDetails ›

RecruitingPhase 2

Cannabis as a Complementary Treatment in Multiple Sclerosis

Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Cannabis oil vs placebo

250 participantsDetails ›

RecruitingPhase 2

Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)

Sponsor: S. Andrea Hospital

Bacille Calmette-Guerin vaccine · Placebo

100 participantsDetails ›

RecruitingPhase 2

Nicotinamide Riboside Supplementation In Progressive Multiple Sclerosis

Sponsor: Haukeland University Hospital

Nicotinamid riboside · Placebo

300 participantsDetails ›

RecruitingPhase 2

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Sponsor: Institute of Psychiatry and Neurology, Warsaw

Cladribine Subcutaneous Injection · 0.9% Chloride Injection Sodium

188 participantsDetails ›

By invitation onlyPhase 1

Quantum-Synaptic Immunotherapy Mapping Using Low-Frequency Electromagnetic Resonance and Machine Learning-Based Cytokine Forecasting

Sponsor: Truway Health, Inc.

Low-Frequency Electromagnetic Resonan… · Sham Resonance Device (Inactive Control)

1 state120 participantsDetails ›

By invitation onlyPhase 2

Effects of Antiviral Therapies on Epstein-Barr Virus Replication

Sponsor: Massachusetts General Hospital

Truvada (tenofovir/emtricitabine)

1 state50 participantsDetails ›

By invitation onlyPhase 2

A Study of Imaging in Demyelinating Diseases

Sponsor: Mayo Clinic

C-11 ER176 Radiotracer · C11 Pittsburgh Compound B

1 state200 participantsDetails ›

By invitation onlyPhase 2

Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

Sponsor: Universidad Nacional Autonoma de Mexico

IV Methylprednisolone administration · Nasal Methylprednisolone (MT)

80 participantsDetails ›

Closed to new patientsPhase 2

A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis

Sponsor: Eli Lilly and Company

LY3541860 · Placebo

5 states63 participantsDetails ›

Closed to new patientsPhase 2

Ketamine for Multiple Sclerosis Fatigue

Sponsor: Johns Hopkins University

Ketamine · Midazolam

1 state110 participantsDetails ›

Closed to new patientsPhase 1

MitoQ for Fatigue in Multiple Sclerosis (MS)

Sponsor: VA Office of Research and Development

20 mg MitoQ · Placebo

1 state45 participantsDetails ›

Closed to new patientsPhase 1

Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis

Sponsor: Haukeland University Hospital

MSCs · Saline

18 participantsDetails ›

Closed to new patientsPhase 2

Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis

Sponsor: Emmanuelle Waubant, MD PhD

N-acetyl cysteine · Placebo

1 state98 participantsDetails ›

Closed to new patientsPhase 2

Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases

Sponsor: Fred Hutchinson Cancer Center

Anti-Thymocyte Globulin · Autologous Hematopoietic Stem Cell Tr…

2 states53 participantsDetails ›

Closed to new patientsPhase 2

Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis

Sponsor: Judit Pich

Autologous peripheral blood different… · Placebo

45 participantsDetails ›

Closed to new patientsPhase 2

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)

Sponsor: Hoffmann-La Roche

Fenebrutinib · Placebo

2 states109 participantsDetails ›

Closed to new patientsPhase 2

Cannabis (THC vs. CBD) in Multiple Sclerosis

Sponsor: University of Calgary

THC · CBD

30 participantsDetails ›

Closed to new patientsPhase 2

A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis

Sponsor: Hoffmann-La Roche

Ocrelizumab

5 states23 participantsDetails ›

Closed to new patientsPhase 2

HB-adMSCs for the Treatment of Patients With Multiple Sclerosis

Sponsor: Hope Biosciences Research Foundation

Autologous HB-adMSCs

1 state10 participantsDetails ›

Closed to new patientsPhase 2

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Sponsor: Zenas BioPharma (USA), LLC

Obexelimab · Placebo

11 states93 participantsDetails ›

Closed to new patientsPhase 2

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Sponsor: Sanofi

SAR441344 IV · placebo IV

4 states129 participantsDetails ›

Closed to new patientsPhase 2

ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis

Sponsor: Queen Mary University of London

Cladribine (MAVENCLAD®) · Placebo

204 participantsDetails ›

Closed to new patientsPhase 2

Metformin Add-on Clinical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neurodegeneration

Sponsor: University Hospital, Antwerp

Metformin Hydrochloride 850 mg Oral T… · Placebo

120 participantsDetails ›

Closed to new patientsPhase 1

Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis

Sponsor: Abu Dhabi Stem Cells Center

Extracorporeal Photopheresis · MS standard of care

15 participantsDetails ›

Closed to new patientsPhase 2

KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis

Sponsor: Kyverna Therapeutics

KYV-101 · Standard lymphodepletion regimen

1 state120 participantsDetails ›

Closed to new patientsPhase 2

Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS

Sponsor: Mapi Pharma Ltd.

GA Depot 40mg once monthly · GA Depot 25mg once monthly

30 participantsDetails ›

Closed to new patientsPhase 2

Adderall XR and Cognitive Impairment in MS

Sponsor: Sarah Morrow

Adderall XR

180 participantsDetails ›

Closed to new patientsPhase 2

Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

tolebrutinib 60mg · tolebrutinib 120mg

1 state12 participantsDetails ›

Closed to new patientsPhase 2

Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis

Sponsor: Immunic AG

IMU-838 · Placebo matching IMU-838

6 states450 participantsDetails ›

Closed to new patientsPhase 2

MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)

Sponsor: Immunic AG

IMU-838 (30 mg/day) · IMU-838 (45 mg/day)

210 participantsDetails ›

MS trials by phase

Phase 3 (49)Phase 1 (43)Phase 4 (19)

The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.